Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050

09 September 2026

National Stock Exchange of India Limited
Scrip Symbol: SUNPHARMA

BSE Limited
Scrip Code: 524715

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Incorporation of a Subsidiary Company

This is to inform you that "Sun Pharma Global Treasury Centre IFSC Limited" has been incorporated on 08 September 2026 as an indirect wholly owned subsidiary of the Company in the International Financial Services Centre at GIFT City, Gandhinagar, Gujarat, India.

The disclosures required under Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 are enclosed as **Annexure A**.

For **Sun Pharmaceutical Industries Limited**
Anoop Anjanikumar Deshpande
Digitally signed by Anoop Anjanikumar Deshpande
Date: 2026.09.09 14:50:21 +05'30'
(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983

Sun Pharmaceutical Industries Limited
Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050

Annexure A

Disclosure under Para A of Part A of Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Sl. No.	Particulars	Information
a)	Name of the target entity, details in brief such as size, turnover etc.	Sun Pharma Global Treasury Centre IFSC Limited, an indirect wholly owned subsidiary of the Company, incorporated in GIFT City IFSC, Gandhinagar, Gujarat. Being newly incorporated, it has not commenced operations and has no turnover.
b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	The entity has been newly incorporated as a wholly owned subsidiary of Sun Pharma Laboratories Limited. The promoter/promoter group has no interest in the entity except through the Sun Pharma Group.
c)	Industry to which the entity being acquired belongs	Financial services, including global treasury and cash management services.
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	To operate as the Global Treasury Centre for the Sun Pharma Group and undertake treasury, funding, liquidity, cash management and other permissible financial activities.
e)	Brief details of any governmental or regulatory approvals required for the acquisition	Registration/approval from the International Financial Services Centres Authority will be obtained for undertaking the proposed activities in GIFT City IFSC.
f)	Indicative time period for completion of the acquisition	Not applicable, as the entity has been newly incorporated.
g)	Nature of consideration - whether cash consideration or share swap and details of the same	Subscription to the initial equity share capital in cash.
h)	Cost of acquisition or the price at which the shares are acquired	Initial subscription to equity share capital of approximately INR. 9.50 Crore.
i)	Percentage of shareholding/ control acquired and/ or number of shares acquired	100%, held through Sun Pharma Laboratories Limited, including its nominee shareholders.
j)	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Incorporated on 08 September 2026 in India to operate as the Global Treasury Centre for the Sun Pharma Group. Being newly incorporated, it has no operating history or turnover.